ArticleNature communications2021
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport.NPJ vaccines · 2025Article
- mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice.Molecular therapy. Nucleic acids · 2024Article
- Increased Susceptibility ofViruses · 2024Article
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Sequence-Optimized mRNA Vaccines Against Infectious Disease.Methods in molecular biology (Clifton, N.J.) · 2024Article
- mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents.NPJ vaccines · 2023Article
- Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications.Life (Basel, Switzerland) · 2023Review
- Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.Nature communications · 2023Article
- Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.Vaccines · 2023Article
- Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.Frontiers in immunology · 2023Article
- Pre-clinical models to define correlates of protection for SARS-CoV-2.Frontiers in immunology · 2023Review
- No Evidence for the Presence of SARS-CoV-2 in Bank Voles and Other Rodents in Germany, 2020-2022.Pathogens (Basel, Switzerland) · 2022Article
- Compellingly high SARS-CoV-2 susceptibility of Golden Syrian hamsters suggests multiple zoonotic infections of pet hamsters during the COVID-19 pandemic.Scientific reports · 2022Article
- mRNA vaccines induce rapid antibody responses in mice.NPJ vaccines · 2022Article
- High viral loads: what drives fatal cases of COVID-19 in vaccinees? - an autopsy study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.Open forum infectious diseases · 2022Article
- Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2.NPJ vaccines · 2022Article
- Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic.Exploration (Beijing, China) · 2022Review
- COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants.iScience · 2022Article
- Of mice and human-specific long noncoding RNAs.Mammalian genome : official journal of the International Mammalian Genome Society · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Funding
Abstract
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.